Lanean...
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration for patients with advanced or metastatic...
Gorde:
| Argitaratua izan da: | J Adv Pract Oncol |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Harborside Press LLC
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7863123/ https://ncbi.nlm.nih.gov/pubmed/33604101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.4.8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|